Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Biotechnology

Editor-in-Chief

ISSN (Print): 1389-2010
ISSN (Online): 1873-4316

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

The Role of Serum Calprotectin as a New Marker in Abdominal Aortic Aneurysms – A Preliminary Report

Author(s): Willy Hauzer, Stanisław Ferenc, Joanna Rosińczuk* and Jan Gnus

Volume 22, Issue 4, 2021

Published on: 17 November, 2020

Page: [508 - 513] Pages: 6

DOI: 10.2174/1389201021666201117095215

Price: $65

Abstract

Background: Abdominal Aortic Aneurysm (AAA) remains a surgical challenge. There are many recognizable markers associated with the formation of AAA. Previous experiments carried out on animal models have shown a correlation between serum calprotectin and the occurrence of AAA.

Objective: This study aimed to evaluate the level of calprotectin as a potential diagnostic biomarker in patients with diagnosed AAA.

Methods: The study group consisted of 75 patients aged 35-75 years assigned to two groups: a control group (n=43) of healthy subjects without AAA and a study group (n=32) of patients with a diagnosed AAA. The first calprotectin test was performed upon patient admission to the hospital, and the second control test was performed after three months. The concentration of calprotectin in plasma was determined using the Immunoenzymatic Method (ELISA) with the commercially available Assaypro Kit (AssayMax™ Human Calprotectin ELISA Kit), as well as the sandwich method with polyclonal antibodies to human calprotectin and peroxidase enzyme.

Results & Discussion: Serum calprotectin levels in AAA patients were three times higher than in healthy subjects (p<0.05). A statistically significant twofold decrease in calprotectin concentration was observed after AAA surgery compared to the control group (p<0.05).

Conclusion: Calprotectin levels can be an important marker in the detection of AAA. In conclusion, AAA patients showed a threefold increase in serum calprotectin level and a twofold decrease in this marker after AAA surgery.

Keywords: Abdominal aortic aneurysm, calprotectin, diagnostic marker, atherosclerosis, immunoenzymatic method, surgery.

« Previous Next »
Graphical Abstract

[1]
Kuivaniemi, H.; Ryer, E.J.; Elmore, J.R.; Tromp, G. Understanding the pathogenesis of abdominal aortic aneurysms. Expert Rev. Cardiovasc. Ther., 2015, 13(9), 975-987.
[http://dx.doi.org/10.1586/14779072.2015.1074861] [PMID: 26308600]
[2]
Xenos, M.; Labropoulos, N.; Rambhia, S.; Alemu, Y.; Einav, S.; Tassiopoulos, A.; Sakalihasan, N.; Bluestein, D. Progression of abdominal aortic aneurysm towards rupture: refining clinical risk assessment using a fully coupled fluid-structure interaction method. Ann. Biomed. Eng., 2015, 43(1), 139-153.
[http://dx.doi.org/10.1007/s10439-014-1224-0] [PMID: 25527320]
[3]
Annambhotla, S.; Bourgeois, S.; Wang, X.; Lin, P.H.; Yao, Q.; Chen, C. Recent advances in molecular mechanisms of abdominal aortic aneurysm formation. World J. Surg., 2008, 32(6), 976-986.
[http://dx.doi.org/10.1007/s00268-007-9456-x] [PMID: 18259804]
[4]
Zommorodi, S.; Leander, K.; Roy, J.; Steuer, J.; Hultgren, R. Understanding abdominal aortic aneurysm epidemiology: socioeconomic position affects outcome. J. Epidemiol. Community Health, 2018, 72(10), 904-910.
[http://dx.doi.org/10.1136/jech-2018-210644] [PMID: 29967003]
[5]
Ullery, B.W.; Hallett, R.L.; Fleischmann, D. Epidemiology and contemporary management of abdominal aortic aneurysms. Abdom. Radiol. (N.Y.), 2018, 43(5), 1032-1043.
[http://dx.doi.org/10.1007/s00261-017-1450-7] [PMID: 29313113]
[6]
Aggarwal, S.; Qamar, A.; Sharma, V.; Sharma, A. Abdominal aortic aneurysm: A comprehensive review. Exp. Clin. Cardiol., 2011, 16(1), 11-15.
[7]
Petriceks, A.H.; Olivas, J.C.; Salmi, D. Educational Case: Symptomatic but Unruptured Abdominal Aortic Aneurysm; Acad Pathol, 2018, p. 52374289518798560.
[http://dx.doi.org/10.1177/2374289518798560] [PMID: 30327791]
[8]
Wanhainen, A.; Verzini, F.; Van Herzeele, I.; Allaire, E.; Bown, M.; Cohnert, T.; Dick, F.; van Herwaarden, J.; Karkos, C.; Koelemay, M.; Kölbel, T.; Loftus, I.; Mani, K.; Melissano, G.; Powell, J.; Szeberin, Z.; de Borst, G.J.; Chakfe, N.; Debus, S.; Hinchliffe, R.; Kakkos, S.; Koncar, I.; Kolh, P.; Lindholt, J.S.; de Vega, M.; Vermassen, F. Document Reviewers; Björck, M.; Cheng, S.; Dalman, R.; Davidovic, L.; Donas, K.; Earnshaw, J.; Eckstein, H.H.; Golledge, J.; Haulon, S.; Mastracci, T.; Naylor, R.; Ricco, J.B.; Verhagen, H. Esvs Guidelines Committee. Editor’s Choice - European Society for Vascular Surgery (ESVS) 2019 Clinical Practice Guidelines on the Management of Abdominal Aorto-iliac Artery Aneurysms. Eur. J. Vasc. Endovasc. Surg., 2019, 57(1), 8-93.
[http://dx.doi.org/10.1016/j.ejvs.2018.09.020] [PMID: 30528142]
[9]
Golledge, J.; Shi, G-P.; Norman, P. , 2011.
[10]
Groeneveld, M.E.; Meekel, J.P.; Rubinstein, S.M.; Merkestein, L.R.; Tangelder, G.J.; Wisselink, W.; Truijers, M.; Yeung, K.K. Systematic Review of Circulating, Biomechanical, and Genetic Markers for the Prediction of Abdominal Aortic Aneurysm Growth and Rupture. J. Am. Heart Assoc., 2018, 7(13)e007791
[http://dx.doi.org/10.1161/JAHA.117.007791] [PMID: 29960996]
[11]
Wołoszko, T.; Skórski, M.; Kwasiborski, P.; Kmin, E.; Gałązka, Z.; Pogorzelski, R. Influence of Selective Biochemical and Morphological Agents on Natural History of Aneurysm of Abdominal Aorta Development. Med. Sci. Monit., 2016, 22, 431-437.
[http://dx.doi.org/10.12659/MSM.893639] [PMID: 26859744]
[12]
Lindberg, S.; Zarrouk, M.; Holst, J.; Gottsäter, A. Inflammatory markers associated with abdominal aortic aneurysm. Eur. Cytokine Netw., 2016, 27(3), 75-80.
[http://dx.doi.org/10.1684/ecn.2016.0381] [PMID: 27910812]
[13]
Urbonavicius, S.; Urbonaviciene, G.; Honoré, B.; Henneberg, E.W.; Vorum, H.; Lindholt, J.S. Potential circulating biomarkers for abdominal aortic aneurysm expansion and rupture--a systematic review. Eur. J. Vasc. Endovasc. Surg., 2008, 36(3), 273-280.
[http://dx.doi.org/10.1016/j.ejvs.2008.05.009] [PMID: 18639476]
[14]
Kotsis, T. Predictions and insights for the abdominal aortic aneurysm. J. Thorac. Dis., 2018, 10(11), 5982-5984.
[http://dx.doi.org/10.21037/jtd.2018.10.15] [PMID: 30622768]
[15]
Nakano, K.; Wada, K.; Nomura, R.; Nemoto, H.; Inaba, H.; Kojima, A.; Naka, S.; Hokamura, K.; Mukai, T.; Nakajima, A.; Umemura, K.; Kamisaki, Y.; Yoshioka, H.; Taniguchi, K.; Amano, A.; Ooshima, T. Characterization of aortic aneurysms in cardiovascular disease patients harboring Porphyromonas gingivalis. Oral Dis., 2011, 17(4), 370-378.
[http://dx.doi.org/10.1111/j.1601-0825.2010.01759.x] [PMID: 21029263]
[16]
Angel, K.; Provan, S.A.; Fagerhol, M.K.; Mowinckel, P.; Kvien, T.K.; Atar, D. Effect of 1-year anti-TNF-α therapy on aortic stiffness, carotid atherosclerosis, and calprotectin in inflammatory arthropathies: a controlled study. Am. J. Hypertens., 2012, 25(6), 644-650.
[http://dx.doi.org/10.1038/ajh.2012.12] [PMID: 22378036]
[17]
Nakatani, Y.; Yamazaki, M.; Chazin, W.J.; Yui, S. Regulation of S100A8/A9 (calprotectin) binding to tumor cells by zinc ion and its implication for apoptosis-inducing activity. Mediators Inflamm., 2005, 2005(5), 280-292.
[http://dx.doi.org/10.1155/MI.2005.280] [PMID: 16258195]
[18]
Pedersen, L.; Nybo, M.; Poulsen, M.K.; Henriksen, J.E.; Dahl, J.; Rasmussen, L.M. Plasma calprotectin and its association with cardiovascular disease manifestations, obesity and the metabolic syndrome in type 2 diabetes mellitus patients. BMC Cardiovasc. Disord., 2014, 14, 196.
[http://dx.doi.org/10.1186/1471-2261-14-196] [PMID: 25527236]
[19]
Kruzliak, P.; Novák, J.; Novák, M.; Fodor, G.J. Role of calprotectin in cardiometabolic diseases. Cytokine Growth Factor Rev., 2014, 25(1), 67-75.
[http://dx.doi.org/10.1016/j.cytogfr.2014.01.005] [PMID: 24560084]
[20]
Patelis, N.; Moris, D.; Schizas, D.; Damaskos, C.; Perrea, D.; Bakoyiannis, C.; Liakakos, T.; Georgopoulos, S. Animal models in the research of abdominal aortic aneurysms development. Physiol. Res., 2017, 66(6), 899-915.
[http://dx.doi.org/10.33549/physiolres.933579] [PMID: 28937252]
[21]
Garred, P.; Fosse, E.; Fagerhol, M.K.; Videm, V.; Mollnes, T.E. Calprotectin and complement activation during major operations with or without cardiopulmonary bypass. Ann. Thorac. Surg., 1993, 55(3), 694-699.
[http://dx.doi.org/10.1016/0003-4975(93)90277-O] [PMID: 8452432]
[22]
Moris, D.; Theocharis, S.; Davakis, S.; Patelis, N.; Agrogiannis, G.; Vlachos, I.S.; Spartalis, E.; Athanasiou, A.; Bakoyiannis, C.; Perrea, D.N.; Georgopoulos, S. Serum Calprotectin as a Novel Biomarker in Abdominal Aortic Aneurysm Pathogenesis and Progression: Preliminary Data from Experimental Model in Rats. Curr. Vasc. Pharmacol., 2018, 16(2), 168-178.
[http://dx.doi.org/10.2174/1570161115666170202155724] [PMID: 28155626]
[23]
Henderson, P.; Casey, A.; Lawrence, S.J.; Kennedy, N.A.; Kingstone, K.; Rogers, P.; Gillett, P.M.; Wilson, D.C. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease. Am. J. Gastroenterol., 2012, 107(6), 941-949.
[http://dx.doi.org/10.1038/ajg.2012.33] [PMID: 22370604]
[24]
Diamanti, A.; Panetta, F.; Basso, M.S.; Forgione, A.; Colistro, F.; Bracci, F.; Papadatou, B.; Francalanci, P.; Torroni, F.; Knafelz, D.; Fina, F.; Castro, M. Diagnostic work-up of inflammatory bowel disease in children: the role of calprotectin assay. Inflamm. Bowel Dis., 2010, 16(11), 1926-1930.
[http://dx.doi.org/10.1002/ibd.21257] [PMID: 20310017]
[25]
Pfefferkorn, M.D.; Boone, J.H.; Nguyen, J.T.; Juliar, B.E.; Davis, M.A.; Parker, K.K. Utility of fecal lactoferrin in identifying Crohn disease activity in children. J. Pediatr. Gastroenterol. Nutr., 2010, 51(4), 425-428.
[http://dx.doi.org/10.1097/MPG.0b013e3181d67e8f] [PMID: 20562721]
[26]
Aomatsu, T.; Yoden, A.; Matsumoto, K.; Kimura, E.; Inoue, K.; Andoh, A.; Tamai, H. Fecal calprotectin is a useful marker for disease activity in pediatric patients with inflammatory bowel disease. Dig. Dis. Sci., 2011, 56(8), 2372-2377.
[http://dx.doi.org/10.1007/s10620-011-1633-y] [PMID: 21394462]
[27]
Kallel, L.; Ayadi, I.; Matri, S.; Fekih, M.; Mahmoud, N.B.; Feki, M.; Karoui, S.; Zouari, B.; Boubaker, J.; Kaabachi, N.; Filali, A. Fecal calprotectin is a predictive marker of relapse in Crohn’s disease involving the colon: a prospective study. Eur. J. Gastroenterol. Hepatol., 2010, 22(3), 340-345.
[http://dx.doi.org/10.1097/MEG.0b013e32832bab49] [PMID: 19581809]
[28]
van Rheenen, P.; de Vijver, E.; Fidler, V. Faecal Calprotectin for Screening of Patients with Suspected Inflammatory Bowel Disease: Diagnostic Meta-Analysis; Centre for Reviews and Dissemination: UK, 2010.
[29]
Burri, E.; Beglinger, C. Faecal calprotectin in the diagnosis of inflammatory bowel disease. Biochem. Med. (Zagreb), 2011, 21(3), 245-253.
[http://dx.doi.org/10.11613/BM.2011.034] [PMID: 22420238]
[30]
Costa, F.; Mumolo, M.G.; Bellini, M.; Romano, M.R.; Ceccarelli, L.; Arpe, P.; Sterpi, C.; Marchi, S.; Maltinti, G. Role of faecal calprotectin as non-invasive marker of intestinal inflammation. Dig. Liver Dis., 2003, 35(9), 642-647.
[http://dx.doi.org/10.1016/S1590-8658(03)00381-5] [PMID: 14563186]
[31]
Johne, B.; Fagerhol, M.K.; Lyberg, T.; Prydz, H.; Brandtzaeg, P.; Naess-Andresen, C.F.; Dale, I. Functional and clinical aspects of the myelomonocyte protein calprotectin. Mol. Pathol., 1997, 50(3), 113-123.
[http://dx.doi.org/10.1136/mp.50.3.113] [PMID: 9292145]

Rights & Permissions Print Cite
Article Metrics
15
1
© 2024 Bentham Science Publishers | Privacy Policy